ESTRO 2024 - Abstract Book

S1980

Clinical - Mixed sites, palliation

ESTRO 2024

Conclusion:

90-day mortality following curative intent radiotherapy for head and neck cancer, and lung cancer varied across NHS Trusts, with some Trusts identified as outliers. The 90-day mortality rates presented here are crude rates not incorporating baseline patient characteristics or distinguishing between disease-related, treatment related and co morbidity related death. Consequently, a provider with high use of radical/adjuvant radiotherapy (sometimes referred to as more aggressive treatment decision-making) may be found to have higher than expected 90-day mortality in the same way as one where support services are less robust than necessary. As such, where a provider is identified as outlying, there is a need to recognise all these factors when considering how best to incorporate this information into future decision-making and service planning.

Keywords: Health services

References:

[1]

DoH.

Improving

Outcomes:

A

Strategy

for

Cancer

[Internet].

2011.

Available

from:

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213785/dh_123394.pdf

[2] Spencer K et al ‘Caution is required in the implementation of 90-day mortality indicators for radiotherapy in a curative setting: A retrospective population- based analysis of over 16,000 episodes’ Radiotherapy and Oncology Volume 125, Issue 1, October 2017, Pages 140-146

[3] Osborne GE, Spendley DG, Nikapota AD. A national standard for early mortality after external beam radiotherapy? Clin Oncol R Coll Radiol. 2013 Sep;25(9):565.

[4] NHS England – Radiotherapy Quality Dashboard Metrics. Available from: https://www.england.nhs.uk/wp content/uploads/2019/03/radiotherapy-adults-dashboard-metric-definitions-19-20-v2.pdf